Mitigation effect of galangin against aortic dysfunction and hypertrophy in rats with metabolic syndrome

Poungrat Pakdeechote; Anuson Poasakate; Patoomporn Prasatthong; Prapassorn Potue; Juthamas Khamseekaew; Putcharawipa Maneesai

doi:10.1016/j.heliyon.2023.e16500

Mitigation effect of galangin against aortic dysfunction and hypertrophy in rats with metabolic syndrome

Heliyon. 2023 May 19;9(5):e16500. doi: 10.1016/j.heliyon.2023.e16500. eCollection 2023 May.

Authors

Poungrat Pakdeechote¹, Anuson Poasakate¹, Patoomporn Prasatthong², Prapassorn Potue¹, Juthamas Khamseekaew¹, Putcharawipa Maneesai¹

Affiliations

¹ Department of Physiology, Faculty of Medicine, Khon Kaen University, Khon Kaen, 40002, Thailand.
² Department of Health Science, Faculty of Science and Technology, Nakhon Sawan Rajabhat University, Nakhon Sawan 60000, Thailand.

Abstract

Vascular alterations induced by a high-fat diet (HFD) are involved in the development of hypertension. Galangin, a flavonoid, is the major active compound isolated from galangal and propolis. The objective of this study was to investigate the effect of galangin on aortic endothelial dysfunction and hypertrophy, and the mechanisms involved in HFD-induced metabolic syndrome (MS) in rats. Male Sprague-Dawley rats (220-240 g) were separated into three groups: control + vehicle, MS + vehicle, and MS + galangin (50 mg/kg). Rats with MS received HFD plus 15% fructose solution for 16 weeks. Galangin or vehicle was orally administered daily for the final four weeks. Galangin reduced body weight and mean arterial pressure in HFD rats (p < 0.05). It also reduced circulating fasting blood glucose, insulin, and total cholesterol levels (p < 0.05). Impaired vascular responses to the exogenous acetylcholine observed in the aortic ring of HFD rats were restored by galangin (p < 0.05). However, the response to sodium nitroprusside did not differ between the groups. Galangin enhanced the expression of the aortic endothelial nitric oxide synthase (eNOS) protein and increased circulating nitric oxide (NO) levels in the MS group (p < 0.05). Aortic hypertrophy in HFD rats was alleviated by galangin (p < 0.05). Increases in tumour necrosis factor-alpha (TNF-α), interleukin (IL)-6 levels, angiotensin-converting enzyme activity and angiotensin II (Ang II) concentrations in rats with MS were suppressed in galangin treated group (p < 0.05). Furthermore, galangin reduced the upregulation of angiotensin II type I receptor (AT1R) and transforming growth factor-beta (TGF-β) expression in rats with MS (p < 0.05). In conclusion, galangin alleviates metabolic disorders and improves aortic endothelial dysfunction and hypertrophy in the MS group. These effects were consistent with increased NO availability, reduced inflammation, and suppressing Ang II/AT1R/TGF-β signalling pathway.

Keywords: Galangin; Metabolic syndrome; Vascular function.